# SciBen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sciben

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.scibenbio.com
- Latest round: Angel (May 22, 2024)
- Investors on record: 1

## About

Founded in 2022 and based in Hefei, China, SciBen is a biotechnology company that focuses on the research and development of specific antibody preparations and related products. It was formerly known as GenuIN Biotech LLC in the United States. SciBen has an R&D and production base, covering an area of 2400 square meters. The company cooperated with Tsinghua University, NIH Infectious Disease Research Institute, China CDC, and other universities and institutions. In May 2024, SciBen closed an angel funding.

SciBen's main business is the development of specific antibody formulations based on its ShGE gene silencing platform. The platform adopts lentivirus-mediated shRNA (Short hairpin RNA) interference technology. Its main products include Monoclonal Antibodies, Lentivirus, Cell Tissue Lysates, ECL Chemiluminescent Kits, etc. Its Lentivirus does not replicate autonomously and is not harmful to the operator and the environment. The company also provides customized services such as antibody specificity verification and lentivirus construction.

The company generates revenue by providing specific antibody preparations and related products.

The company will use the angel funding to develop specific antibody and lentivirus libraries, stable transient cell line libraries, and cell lysate libraries based on the ShGE gene silencing platform, to cooperate with companies in the life sciences industry, as well as to accelerate R&D and commercialization.

## Funding rounds

- Angel, May 22, 2024 — October Capital

## Investors

- October Capital (https://capitalatlas.ai/funds/october-capital) — Angel